Thus, in this current study, we evaluate the efficacy of continuing trastuzumab after failure of first-line platinum-based chemotherapy plus trastuzumab in patients with HER2-positive advanced gastric or GEJ adenocarcinoma. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.